CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed
Drug / intervention
Glivec +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00390897
NCT00390897Phase 4Completed
CompareCT.gov

Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia

PETHEMA Foundation·interventional·Posted Oct 23, 2006·Updated Nov 27, 2008

In Brief

A Phase 4 clinical trial evaluating Glivec and Interferon for Chronic Myeloid Leukaemia. Completed, across 51 sites.

Detailed Summary

To compare the complete cytogenetic response rate in patients with newly-diagnosed chronic-phase chronic myeloid leukaemia treated with Glivec® alone or in combination with interferon at low doses

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myeloid Leukaemia
CountriesSpain
Collaborators--

Timeline

Phase 4CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 23, 2006
Enrollment StartJul 1, 2003
Primary CompletionOct 1, 2006
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 19.7 years ago

Interventions

Glivecdrug

Interferondrug